Key Developments For Affymetrix, Inc.
Affymetrix, Inc. (AFFX.O) (Nasdaq)
Affymetrix, Inc. Issues Q4 2009 Revenue Outlook In Line With Analysts' Estimates-Conference Call
Affymetrix, Inc. announced that for the fourth quarter of 2009, it expects revenue to be in the range of between $82 and $85 million. According to Reuters Estimates, analysts on an average are expecting the Company to report revenue of $85 million for the same period.
Affymetrix, Inc. Announces Major Genotyping Project With Kaiser Permanente And University Of California At San Francisco For NIH-Funded Epidemiology Study
Affymetrix, Inc. announced that the Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) and the University of California at San Francisco (UCSF) have entered into an agreement with Affymetrix to support genome-wide analyses of DNA samples from 100,000 Kaiser Permanente members. The members have volunteered for a large-scale research program designed to create a new resource for studying disease, health, and aging. Scientists from the program will use the just-launched Axiom Genotyping Solution, which delivers high-throughput, automated technology and enables researchers to find common genetic variations associated with complex disease.
Affymetrix, Inc. Launches New Platform For Genotyping
Affymetrix, Inc. announced the launch of the Axiom Genotyping Solution, its array technology designed to match the significant rise in genetic content generated by government and privately funded sequencing projects. This high-throughput, automated platform enables researchers to find novel genetic variations associated with complex disease.
Affymetrix, Inc. and Beckman Coulter, Inc. Join Forces To Provide Robust, Automated Target Preparation Solutions
Affymetrix, Inc. and Beckman Coulter, Inc. announced that they have entered into an agreement to offer researchers co-developed products from the microarrays and automated liquid handlers. The collaboration will provide scientists with optimized, robust solutions for genomic research, fortified by end-to-end support. The partnership will yield an expanding list of Affymetrix-validated automated target preparation methods, developed on an Affymetrix-specific configuration of Beckman Coulter's precise and reliable Biomek FXp Dual Arm Multichannel-Span 8 Liquid Handler. This platform will provide researchers with standardized systems that include all components necessary to run Affymetrix genotyping and gene expression assays. Automated target preparation solutions from Affymetrix and Beckman Coulter are for research use only and are not for use in diagnostic procedures.
Affymetrix, Inc. And NIAID Offers New Affymetrix Array For Identification of E. Coli and Shigella
Affymetrix, Inc. and the National Institute of Allergy and Infectious Diseases (NIAID) announced the launch of the Affymetrix FDA-ECSG custom microarray for identifying and discriminating between different strains of E. coli and Shigella. This custom array was developed for the FDA and is now available to researchers worldwide. The Company and JCVI have collaborated to make this array available from the PFGRC at no cost to researchers through the NIAID-sponsored PFGRC microarray application process.
